184 related articles for article (PubMed ID: 12594127)
41. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
[TBL] [Abstract][Full Text] [Related]
42. Anti-tumor necrotic factor antibody for treatment of neuro-Behçet's disease, a case report.
Borhani Haghighi A; Safari A
Clin Neurol Neurosurg; 2008 Mar; 110(3):315-6. PubMed ID: 18053588
[No Abstract] [Full Text] [Related]
43. Worsening of osteomalacia in a patient successfully treated for neuro-Behçet's disease with infliximab.
Madanat WY; Madanat AY
Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S128-9. PubMed ID: 19026133
[No Abstract] [Full Text] [Related]
44. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
Morris DS; Gavin MP; Sturrock RD
Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
[No Abstract] [Full Text] [Related]
45. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.
Belzunegui J; López L; Paniagua I; Intxausti JJ; Maíz O
Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S133-4. PubMed ID: 19026138
[No Abstract] [Full Text] [Related]
46. Infliximab for the treatment of refractory Adamantiades-Behçet disease with articular, intestinal, cerebral and ocular involvement.
Donghi D; Mainetti C
Dermatology; 2010; 220(3):282-6. PubMed ID: 20110641
[No Abstract] [Full Text] [Related]
47. Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab.
Jalili A; Kinaciyan T; Barisani T; Peck-Radosavljevic M; Stingl G; Geusau A; Wöhrl S
Iran J Immunol; 2009 Mar; 6(1):55-8. PubMed ID: 19293479
[No Abstract] [Full Text] [Related]
48. Adalimumab: a new modality for Behçet's disease?
van Laar JA; Missotten T; van Daele PL; Jamnitski A; Baarsma GS; van Hagen PM
Ann Rheum Dis; 2007 Apr; 66(4):565-6. PubMed ID: 17124248
[No Abstract] [Full Text] [Related]
49. Refractory neuro-Behçet treated by tocilizumab: a case report.
Urbaniak P; Hasler P; Kretzschmar S
Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S73-5. PubMed ID: 23020826
[TBL] [Abstract][Full Text] [Related]
50. Antitumor necrosis factor monoclonal antibody therapy in a woman with severe Adamantiades-Behçet's disease.
Behrens F; Zollner T; Moeller B; Kaltwasser JP; Kaufmann R; Ochsendorf FR
Adv Exp Med Biol; 2003; 528():561-2. PubMed ID: 12918764
[No Abstract] [Full Text] [Related]
51. Successful long-term treatment of refractory Adamantiades-Behçet's disease (ABD) with infliximab: report of two patients.
Katsiari CG; Theodossiadis PG; Kaklamanis PG; Markomichelakis NN; Sfikakis PP
Adv Exp Med Biol; 2003; 528():551-5. PubMed ID: 12918762
[No Abstract] [Full Text] [Related]
52. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
53. Successful use of infliximab in a patient with neuro-Behçet's disease.
Abalos-Medina GM; Sánchez-Cano D; Ruiz-Villaverde G; Ruiz-Villaverde R; Quirosa Flores S; Raya Alvarez E
Int J Rheum Dis; 2009 Sep; 12(3):264-6. PubMed ID: 20374357
[TBL] [Abstract][Full Text] [Related]
54. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
Maini RN; Taylor PC; Paleolog E; Charles P; Ballara S; Brennan FM; Feldmann M
Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I56-60. PubMed ID: 10577974
[No Abstract] [Full Text] [Related]
55. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.
Van den Bosch F; Baeten D; Kruithof E; De Keyser F; Mielants H; Veys EM
Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii33-6. PubMed ID: 11890649
[No Abstract] [Full Text] [Related]
56. Mimicry between intestinal Behçet's disease and inflammatory bowel disease.
Rodrigues-Pinto E; Magro F; Pimenta S; Guimarães J; Macedo G
J Crohns Colitis; 2014 Jul; 8(7):714-5. PubMed ID: 24389388
[No Abstract] [Full Text] [Related]
57. [Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease].
Tanaka H; Sugita S; Yamada Y; Kawaguchi T; Iwanaga Y; Kamoi K; Yokota M; Takase H; Mochizuki M
Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):87-95. PubMed ID: 20187505
[TBL] [Abstract][Full Text] [Related]
58. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease.
Giansanti F; Barbera ML; Virgili G; Pieri B; Emmi L; Menchini U
Eur J Ophthalmol; 2004; 14(5):445-8. PubMed ID: 15506610
[TBL] [Abstract][Full Text] [Related]
59. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
60. A case of primary cerebral vasculitis.
Herath SS; Law DB; Stride PJ; Heazlewood VJ; Gaffney LS
Med J Aust; 2008 May; 188(9):547-9. PubMed ID: 18459934
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
